238 related articles for article (PubMed ID: 30672165)
41. Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy.
Sauer M; Weinrich JM; Fraune C; Salomon G; Tennstedt P; Adam G; Beyersdorff D
Eur J Radiol; 2018 Jan; 98():187-192. PubMed ID: 29279161
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.
Harmon SA; Gesztes W; Young D; Mehralivand S; McKinney Y; Sanford T; Sackett J; Cullen J; Rosner IL; Srivastava S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Dobi A; Sesterhenn IA; Turkbey B
Radiology; 2021 Jun; 299(3):613-623. PubMed ID: 33847515
[TBL] [Abstract][Full Text] [Related]
43. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI.
Chung DY; Koh DH; Goh HJ; Kim MS; Lee JS; Jang WS; Choi YD
BMC Cancer; 2018 Nov; 18(1):1057. PubMed ID: 30382916
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy.
Tanaka T; Kawashima A; Rangel LJ; Schulte PJ; Froemming AT; King BF; Mynderse LA; Karnes RJ
J Urol; 2022 May; 207(5):1038-1047. PubMed ID: 34981952
[TBL] [Abstract][Full Text] [Related]
46. Do Second Primary Cancers Affect the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy? A Propensity Score-Matched Analysis.
Kang M; Jung JW; Oh JJ; Lee S; Hong SK; Lee SE; Byun SS
Clin Genitourin Cancer; 2016 Aug; 14(4):e363-9. PubMed ID: 27105723
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
[TBL] [Abstract][Full Text] [Related]
48. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
[TBL] [Abstract][Full Text] [Related]
49. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
50. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
51. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
52. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
Hegde JV; Veruttipong D; Said JW; Reiter RE; Steinberg ML; King CR; Kishan AU
Urology; 2017 Sep; 107():171-177. PubMed ID: 28552819
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the accuracy of multiparametric magnetic resonance imaging (mpMRI) results with the final pathology findings for radical prostatectomy specimens in the detection of prostate cancer.
Lee CH; Ku JY; Park WY; Lee NK; Ha HK
Asia Pac J Clin Oncol; 2019 Apr; 15(2):e20-e27. PubMed ID: 29920966
[TBL] [Abstract][Full Text] [Related]
54. Effect of preoperative PI-RADS assessment on pathological outcomes in patients who underwent radical prostatectomy.
Peng Q; Xu L; Zhang G; Zhang D; Zhang J; Zhang X; Bai X; Chen L; Jin Z; Sun H
Cancer Imaging; 2023 Nov; 23(1):113. PubMed ID: 38008745
[TBL] [Abstract][Full Text] [Related]
55. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy.
Panebianco V; Villeirs G; Weinreb JC; Turkbey BI; Margolis DJ; Richenberg J; Schoots IG; Moore CM; Futterer J; Macura KJ; Oto A; Bittencourt LK; Haider MA; Salomon G; Tempany CM; Padhani AR; Barentsz JO
Eur Urol Oncol; 2021 Dec; 4(6):868-876. PubMed ID: 33582104
[TBL] [Abstract][Full Text] [Related]
56. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
[TBL] [Abstract][Full Text] [Related]
57. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
[TBL] [Abstract][Full Text] [Related]
58. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
59. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
60. Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion.
Shin N; Park SY
AJR Am J Roentgenol; 2020 Oct; 215(4):913-919. PubMed ID: 32755167
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
